Vol 6, No 5 (2010)
Review paper
Published online: 2011-01-19
Pathophysiological basis of combination of systemic chemiotherapy with EGFR inhibitors
Onkol. Prak. Klin 2010;6(5):236-240.
Abstract
Cancer patients treatment using the combination of systemic chemotherapy with EGFR inhibitors still creates
multiple questions. To date the exact mechanisms of interactions between the two different therapeutic
modalities have not been ultimately explained. It seems that common intercellular apoptosis pathway,
inhibition of DNA repair systems, especially double strand breaks, and antiangiogenic effects play
an important role in the outcome of such combined antineoplastic therapy.
Onkol. Prak. Klin. 2010; 6, 5: 236–240
Keywords:
epidermal growth factor receptorEGFRchemotherapyapoptosisDNA repair systemsangiogenesis
References
- Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3): 183–232.
- Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7(10): 2958–2970.
- Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21(14): 2787–2799.
- Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003; 95(12): 851–867.
- Morelli MP, Cascone T, Troiani T, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16 Suppl 4: iv61–iv68.
- Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother. 2004; 5(7): 1621–1633.
- Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4): 337–345.
- Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004; 22(5): 777–784.
- Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004; 22(5): 785–794.
- Herbst RS, Prager D, Hermann R, et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2004; 22(14_suppl): 7011.
- Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25(12): 1545–1552.
- Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000; 102(1): 1–4.
- Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6): 420–430.
- Schilsky RL. Antimetabolites. In: Perry MC. ed. The chemotherapy source book. Williams & Wilkins, Baltimore 1992: 301–315.
- Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 2003; 22(56): 9063–9074.
- Ingraham HA, Tseng BY, Goulian M. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharmacol. 1982; 21(1): 211–216.
- Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999; 13(2): 152–157.
- Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003; 3(5): 421–429.
- Kastan MB, Lim DS, Kim ST, et al. Multiple signaling pathways involving ATM. Cold Spring Harb Symp Quant Biol. 2000; 65: 521–526.
- Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381): 1322–1326.
- Mauro DJ, De Riel JK, Tallarida RJ, et al. Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells. Mol Pharmacol. 1993; 43(6): 854–857.
- Boku N, Chin K, Hosokawa K, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998; 4(6): 1469–1474.
- Dickson JLB, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol. 2004; 16(3): 255–263.
- Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305(5687): 1163–1167.
- Rutkowski B. Erytropoetyna od odkrycia do zastosowań klinicznych. Makmed, Gdańsk 2001: 16–26.
- Bandyopadhyay D, Mandal M, Adam L, et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem. 1998; 273(3): 1568–1573.
- Yoganathan TN, Costello P, Chen X, et al. Integrin-linked kinase (ILK): a "hot" therapeutic target. Biochem Pharmacol. 2000; 60(8): 1115–1119.
- Galetic I, Andjelkovic M, Meier R, et al. Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase--significance for diabetes and cancer. Pharmacol Ther. 1999; 82(2-3): 409–425.
- Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3): 183–232.
- Jain RK. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science. 2005; 307(5706): 58–62.